Background: Rivaroxaban has gained popularity as an anticoagulant (AC) for stroke prevention in nonvalvular atrial fibrillation (afib) and venous thromboembolism (VTE). Although adverse bleeding events are associated with all AC, lack of point of care testing to measure the effect of rivaroxaban in emergent situations has contributed to perceived increased risk amongst physicians. Methods: To describe a single center experience with trauma and emergency general surgery (EGS) patients taking rivaroxaban and evaluate outcomes compared with patients taking warfarin using a propensity score analysis. Trauma and EGS patients taking rivaroxaban or warfarin for afib/VTE over 2 year period were eligible for inclusion and matched for injury/illness severity in a 1:2 ratio using propensity score matching. In a single quaternary referral center, 192 warfarin patients were matched to 96 rivaroxaban patients. Groups were well matched with no significant difference in age/sex, admission SBP/ HR, admission hemoglobin, ISS (trauma patients), or need for ICU admission. Conditional logistic regression determined association of AC type with bleeding complications, adjusting for age/sex, AC indication, coagulation laboratory values, antiplatelet medications or other AC, comorbidities, renal impairment, and operative intervention. Primary outcome was bleeding complications, defined as hemorrhage during admission or as a presenting problem. Secondary outcomes included invasive interventions, AC reversal, VTE complications, and mortality. Results: There was no difference between rivaroxaban and warfarin for bleeding complications (37% vs 39%, p=0.49), VTE complications (4.2% vs 5.7%, p=0.44), or mortality (4.2% vs 5.8%, p=0.63). Fewer rivaroxaban patients underwent surgical or interventional radiology (IR) procedures during admission (32% vs 43%, p=0.01), but there was no difference in procedures specifically for bleeding (10% vs 12% p=0.68). Rivaroxaban patients less frequently underwent AC reversal (34% vs 46%, p=0.01) or received multiple reversal agents (20% vs 29%, p=0.02). Regression analysis confirmed AC type was not associated with bleeding complications (rivaroxaban vs warfarin RR 1.02; 95%CI 0.85-1.22, p=0.85). Conclusion: Reversal of rivaroxaban was less common and required fewer agents while bleeding complications and hemostatic interventions do not appear to be different between these AC types. Level of Evidence: Therapeutic study, level III. (C) 2016 Lippincott Williams & Wilkins, Inc.
from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2iyZQAO
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Reuters Health News from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2rI2pFX
-
The new system cuts out the practice of “over triaging calls” and uses an algorithm to suggest to dispatchers what resources are needed fr...
-
Noninvasive ventilation (NIV) is the first-line treatment of adult patients with exacerbations of cystic fibrosis (CF). High-flow nasal oxyg...
-
The new system is meant to allow people who are hard of hearing, speech-impaired or unable to talk safely on the phone to connect with emerg...
-
Objective: It was hypothesized that adding dedicated afternoon rounds for patients’ families to supplement standard family support would imp...
-
International Journal of Environmental Research... Latest Results for Sleep and BreathingIntermitt... Evolutionary Biology News -- S...
-
The American Journal of Emergency Medicine from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2iKBYYz
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου